VCANBIO's subsidiary VUM02 injection has been approved for clinical trials
VCANBIO's wholly-owned subsidiary Wuhan Optics Valley VCANBIO Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration on September 9, 2025, to conduct clinical trials for VUM02 injection. This injection is a cryopreserved cell preparation independently developed by the company, primarily used for the treatment of severe/critical pneumonia
According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that its wholly-owned subsidiary Wuhan Optics Valley VCANBIO Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on September 9, 2025, for the use of VUM02 injection in the treatment of severe/critical pneumonia.
VUM02 injection (human umbilical cord-derived mesenchymal stem cell injection) is a cryopreserved cell preparation independently developed by our company. It is a new drug prepared from selected healthy newborn umbilical cord tissue through in vitro separation, expansion, harvesting, and cryopreservation, with the clinical intended indication for the treatment of severe/critical pneumonia
